MedTrace Logo

TS Stratified Chemotherapy and VEGF Inhibition in Non-Squamous Non-Small Cell Lung Cancer - Stage IV

NCT01674738 · Status: WITHDRAWN · Phase: PHASE2 · Type: INTERVENTIONAL

Last updated 2013-10-11

No results posted yet for this study

Summary

This study wants to determine the activity of a first-line treatment related to Thymidylate Synthetase (TS) Expression. Patients with the diagnosis of non-squamous advanced Non-Small-Cell Lung-Cancer (Stage IV) and without evidence of EGFR mutation may be enclosed in this clinical trial.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

Pemetrexed

500 mg/m2 i.v. on day 1 (three-week cycle)

DRUG

Cisplatin

75 mg/m2 i.v. on day 1 (three-week cycle)

DRUG

Bevacizumab

7,5 mg/kg i.v. on day 1 (three-week cycle)

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Eli Lilly and Company

    collaborator INDUSTRY

  • Aktion Bronchialkarzinom e.V.

    lead OTHER

Principal Investigators

  • Gunther Wiest, MD · Asklepios Klinik Harburg, D-21075 Hamburg, Germany

  • Prof. Dr. Martin Wolf, MD · Klinikum Kassel GmbH, D-34125 Kassel

  • Dr. Monika Serke, MD · Lungenklinik Hemer, D-58675 Hemer, Germany

  • Prof. Dr. Michael Thomas, MD · Thoraxklinik Heidelberg, D-69126 Heidelberg, Germany

  • Rudolf M. Huber, MD · Klinikum der Universität München, D-80336 München, Germany

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01674738 on ClinicalTrials.gov